{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T02:12:11Z","timestamp":1782007931095,"version":"3.54.5"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ramucirumab plus docetaxel combination therapy (DOC\/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients included those with advanced NSCLC with measurable asymptomatic brain metastases that progressed after chemotherapy. Patients were intravenously administered ramucirumab (10\u2009mg\/kg) and docetaxel (60\u2009mg\/m2) every 21-day cycle.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Due to difficulties in accumulating the planned 65 participants, enrollment was terminated early when 25 patients were enrolled. Primary endpoint: Median progression-free survival (PFS) was 3.9 months (95% CI, 1.8-5.3). Secondary endpoints: Median intracranial progression-free survival was 4.6 months (95% CI, 2.5-5.9); median overall survival was 20.9 months (95% CI, 6.6-not possible to estimate); objective response rate was 20% (95% CI, 6.8-40.7); disease control rate was 68% (95% CI, 46.5-85.1). The most common grade 3 or higher toxicities were neutropenia in 10 patients (40%). Neither intracranial hemorrhage nor grade 5 adverse events were observed. Patients with higher serum soluble vascular endothelial growth factor receptor 2 concentrations at the start of treatment had slightly longer PFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No clinical concerns were identified with DOC\/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad013","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T19:04:03Z","timestamp":1681412643000},"page":"551-e454","source":"Crossref","is-referenced-by-count":8,"title":["Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial"],"prefix":"10.1093","volume":"28","author":[{"given":"Keiko","family":"Tanimura","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Uchino","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideharu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanazawa University Hospital , Kanazawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Hiranuma","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Otsu City Hospital , Otsu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-844X","authenticated-orcid":false,"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Uji-Tokushukai Medical Center , Uji , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tanzawa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Teikyo University Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Takumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization, Kanazawa Medical Center , Kanazawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitakyushu Municipal Medical Center , Kitakyushu , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center , Ota , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukuoka University Hospital , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Future Medical Center, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"2","key":"2023060914152194000_CIT0001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:CLIN.0000024761.00373.55","article-title":"Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice","volume":"21","author":"Kim","year":"2004","journal-title":"Clin Exp Metastasis"},{"issue":"17","key":"2023060914152194000_CIT0002","first-page":"4959","article-title":"Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis","volume":"60","author":"Yano","year":"2000","journal-title":"Cancer Res"},{"issue":"8","key":"2023060914152194000_CIT0003","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (brain): a nonrandomized, phase II study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023060914152194000_CIT0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000480702","article-title":"Bevacizumab in combination with platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer with or without brain metastases: a French cohort study (EOLE)","volume":"94","author":"Bennouna","year":"2018","journal-title":"Oncology"},{"issue":"5","key":"2023060914152194000_CIT0005","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9944","key":"2023060914152194000_CIT0006","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet."},{"key":"2023060914152194000_CIT0007","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer"},{"issue":"3","key":"2023060914152194000_CIT0008","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.18632\/oncotarget.6184","article-title":"Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"2023060914152194000_CIT0009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","article-title":"Identification of prognostic factors in patients with brain metastases: a review of 1292 patients","volume":"43","author":"Lagerwaard","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2023060914152194000_CIT0010","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.21037\/jtd.2019.10.49","article-title":"Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis","volume":"11","author":"Zhan","year":"2019","journal-title":"J Thorac Dis"},{"issue":"1","key":"2023060914152194000_CIT0011","first-page":"vdaa038","article-title":"Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases","volume":"2","author":"Berghoff","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"23","key":"2023060914152194000_CIT0012","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1158\/1078-0432.CCR-08-0593","article-title":"VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy","volume":"14","author":"Burstein","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023060914152194000_CIT0013","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/bjc.2013.69","article-title":"Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer","volume":"108","author":"Miles","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"2023060914152194000_CIT0014","first-page":"2939","article-title":"Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion","volume":"36","author":"Tamiya","year":"2016","journal-title":"Anticancer Res"},{"issue":"2","key":"2023060914152194000_CIT0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/ol_00000045","article-title":"Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6","volume":"1","author":"Aoyagi","year":"2010","journal-title":"Oncol Lett."},{"issue":"3","key":"2023060914152194000_CIT0016","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdx767","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume":"29","author":"Tabernero","year":"2018","journal-title":"Ann Oncol"},{"key":"2023060914152194000_CIT0017","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2019.10.026","article-title":"Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study","volume":"127","author":"Van Cutsem","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023060914152194000_CIT0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2011.02.016","article-title":"Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC","volume":"74","author":"Jantus-Lewintre","year":"2011","journal-title":"Lung Cancer"},{"issue":"1","key":"2023060914152194000_CIT0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1009033017809","article-title":"Soluble VEGF receptors","volume":"3","author":"Hornig","year":"1999","journal-title":"Angiogenesis"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/551\/50514491\/oyad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/551\/50514491\/oyad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T16:21:21Z","timestamp":1686327681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/551\/7117810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad013","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,4,13]]}}}